NCT07278089Recruiting
AF Screening in Patients With Abnormal Echocardiographic Parameters
Screening of Atrial Fibrillation/Arrhythmia Events in Patients With Abnormal Echocardiographic Parameters: The Randomized, Prospective SAFE-ECHO Study Design and Rationale
Source: ClinicalTrials.gov · Last updated 11 Dec 2025
Brief summary (registry, in English)
To evaluate the feasibility of specific echocardiographic parameters as criteria for AF screening and to determine the AF detection yield of scheduled extended ECG monitoring compared to contemporary care.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 3000 (estimated)
- First submitted
- 29 Nov 2025
- Start date
- 17 Mar 2025
- Primary completion date
- 31 Dec 2031
- Lead sponsor
- Tze-Fan Chao
- Diseases
- Atrial fibrillation
- NCT number
- NCT07278089
What you commit to
- Study type: Interventional
- Planned participants: 3000
- From 17 Mar 2025 to the primary completion date, 31 Dec 2031
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with a history of AF or atrial flutter, congenital heart disease, acute coronary syndrome undergoing urgent percutaneous coronary intervention within 3 months, uncontrolled hyperthyroidism, end-stage renal disease, unstable hemodynamic status or any known major comorbidities or medical conditions with expected life expectancy less than 1 year are excluded.
Who the study is looking for
- LAE: defined as LAD ≥ 45 mm or LAVI \> 34 ml/m2;
- LVH: defined as LV septal or posterior wall thickness ≥ 15 mm;
- E/e' \> 14;
- grade II or III diastolic dysfunction;
- VHD;
- HF: defined as LVEF \< 40% or LVEF ≥40% with clinical presentation compatible with Framingham criteria, New York Heart Association functional classification II-IV, and N-terminal pro-B type natriuretic peptide (NT-proBNP) \> 125 pg/ml.
Age in the registry: 20 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Taipei Veterans General Hospital Coordinator of this site? Confirm its status | Taipei | Taiwan | Recruiting |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.